No Detail Found!

Role of baricitinib and sotrovimab in the management of COVID-19

Author(s)
Darmadi Darmadi Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Indonesia
Cennikon Pakpahan Department of Biomedical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Sem Samuel Surja Department of Parasitology, School of Medicine and Health Sciences, Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia
Abstract
Objective: To review the role of baricitinib and sotrovimab in managing COVID-19, amidst evolving treatment guidelines and varying efficacy against different virus variants. Methodology: This review utilized online database using specific keywords related to the subject independently performed with manual checks of reference lists for completeness. Results: Baricitinib, authorized with remdesivir for severe COVID-19, reduces mechanical ventilation and ICU admissions without increasing hospital stays, and shows improved mortality and recovery rates, especially when combined with corticosteroids. Sotrovimab, effective in early clinical trials at reducing hospitalizations and adverse events, has shown comparable or superior efficacy to other antivirals but lost authorization for variants like Omicron BA.2. Conclusion: Baricitinib works as a JAK inhibitor with a 2 mg dose recommended for COVID-19, while sotrovimab, a monoclonal antibody, neutralizes SARS-CoV-2 but has limitations against certain variants. Both drugs offer significant benefits in treating severe COVID-19.
Publication Details
Page(s) 678-681
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 49, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Management, COVID-19, Guideline, Baricitinib, sotrovimab.
References
Chowdhury SD,Oommen AM .2020 .. Epidemiology of COVID19. J Dig Endosc, 11 : 3-7.
Ruslie RH,Darmadi D.,Coronavirus D. .2020 .-19 and mental health. Open Access Maced J Med Sci, 8 : 268-71.
Siregar GA,Siregar GP,Darmadi D,Ruslie RH,Injury Liver .2020 .. Open Access Maced J Med Sci, 8 : 154-7.
Siregar GA,Siregar GP,Darmadi D,Review A .2020 .. Open Access Maced J Med Sci, 8 : 52-4.
Ruslie RH,Darmadi D,Siregar GA .2020 .Paediatric immunization practice during coronavirus disease-2019 pandemic. Open Access Maced J Med Sci, 8 : 258-60.
Ruslie RH,Darmadi D,Siregar GA .2020 .Susceptibility of coronavirus disease-19 in pediatric population. Open Access Maced J Med Sci, 8 : 363-5.
.2023 .WHO Coronavirus (COVID-19) Dashboard. , : .
- ,- .2023 .The National Institute for Health and Care Excellence (NICE. COVID-19 Rapid Guideline: Managing COVID19, : .
Bronte V,Ugel S,Tinazzi E,Vella A,De Sanctis F,Canè S .2020 .Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest, 130 : 6409-16.
Petrone L,Petruccioli E,Alonzi T,Vanini V,Cuzzi G,Fard SN .2021 .In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. J Infect, 82 : 58-66.
Sims JT,Krishnan V,Chang CY,Engle SM,Casalini G,Rodgers GH .2021 .Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Aller Clin Immunol, 147 : 107-11.
Kalil AC,Patterson TF,Mehta AK,Tomashek KM,Wolfe CR,Ghazaryan V .2021 .Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med, 384 : 795-807.
Chen C-X,Wang J-J,Li H,Yuan L-T RP,Liang Y. .2021 .JAK-Inhibitors for Coronavirus Disease-2019 (COVID19): A Meta-analysis. Leukemia, 35 : 2616-20.
Selvaraj V,Finn A,Lal A,Khan MS,Dapaah-Afriyie K,Carino GP .2022 .Baricitinib in Hospitalised Patients with COVID-19: A Meta-analysis of Randomized Controlled Trials. Clin Med, 49 : 101489.
Zhang X,Shang L,Fan G,Gu X,Xu J,Wang Y .2022 .The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and MetaAnalysis. Front Med, 8 : 800492.
Limen RY,Sedono R,Sugiarto A,Hariyanto TI .2012 .Janus Kinase (JAK)-Inhibitors and Coronavirus Disease 2019 (Covid-19) Outcomes: A Systematic Review and Metaanalysis. Expert Rev Anti Infect Ther, : 1-10.
Lin Z,Niu J,Xu Y,Qin L,Ding J,Zhou L. .2022 .Clinical Efficacy and Adverse Events of Baricitinib Treatment for Coronavirus Disease‐2019 (COVID‐19): A Systematic Review and Meta‐analysis. J Med Virol, 94 : 1523-34.
Ely EW,Ramanan AV,Kartman CE,de Bono S,Liao R,Piruzeli MLB .2022 .Efficacy and Safety of Baricitinib Plus Standard of Care for The Treatment of Critically Ill Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: An Exploratory, Randomised, Placebocontrolled Trial. Lancet Respir Med, 10 : 327-36.
Wong CKH,Lau KTK,Au ICH,Xiong X,Chung MSH,Leung BYC .2022 .Initiation of Tocilizumab or Baricitinib Were Associated with Comparable Clinical Outcomes Among Patients Hospitalized with COVID-19 and Treated with Dexamethasone. Front Pharmacol, 13 : 866441.
Roddy J,Wells D,Schenck K,Santosh S,Santosh S. Tocilizumab .2022 .Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study. Crit Care Explor, 4 : e0702.
Rodriguez-Garcia JL,Sanchez-Nievas G,ArevaloSerrano J,Garcia-Gomez C,Jimenez-Vizuete JM,Martinez-Alfaro E. Baricitinib JM .2021 .Improves Respiratory Function in Patients Treated with Corticosteroids for SARS-CoV-2 Pneumonia: An Observational Cohort Study. Rheumatology, 60 : 399-407.
So JM,Umeh C,Noriega S,Stratton E,Aseri M,Gupta RC .2021 .Use of Baricitinib in Combination with Remdesivir and Steroid in COVID-19 Treatment: A Multicenter Retrospective Study. Cureus, 13 : e20620.
Russo A,Grimaldi P,Pisaturo M,Onorato L,Coppola N. .2024 .Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data. Front Immunol, 15 : 1295029.
Maher MC,Soriaga LB,Gupta A,Chen YP,di Iulio J,Ledoux S .2022 .Antibody therapy reverses biological signatures of COVID-19 progression. Cell Rep Med, : 3.
0

Citations

0

Downloads

38

Views